bioaffinity technologies inc. - BIAF
BIAF
Close Chg Chg %
1.33 -0.05 -3.76%
Pre-Market
1.28
-0.05 (3.76%)
Volume: 79.58K
Last Updated:
Nov 12, 2024, 4:00 PM EDT
Company Overview: bioaffinity technologies inc. - BIAF
BIAF Key Data
| Open $1.30 | Day Range 1.26 - 1.33 |
| 52 Week Range 1.25 - 3.62 | Market Cap $17.94M |
| Shares Outstanding 13.49M | Public Float 9.34M |
| Beta 3.12 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.90 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 202.95K |
BIAF Performance
| 1 Week | -6.57% | ||
| 1 Month | -32.98% | ||
| 3 Months | -29.28% | ||
| 1 Year | -7.91% | ||
| 5 Years | N/A |
BIAF Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About bioaffinity technologies inc. - BIAF
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
BIAF At a Glance
bioAffinity Technologies, Inc.
22211 West Interstate 10
San Antonio, Texas 78257
| Phone | 1-210-698-5334 | Revenue | 2.53M | |
| Industry | Medical Specialties | Net Income | -7,937,011.00 | |
| Sector | Health Technology | 2023 Sales Growth | 52,627.441% | |
| Fiscal Year-end | 12 / 2024 | Employees | 75 | |
| View SEC Filings |
BIAF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.079 |
| Price to Book Ratio | 2.845 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.505 |
| Enterprise Value to Sales | 4.588 |
| Total Debt to Enterprise Value | 0.136 |
BIAF Efficiency
| Revenue/Employee | 33,766.653 |
| Income Per Employee | -105,826.813 |
| Receivables Turnover | 3.12 |
| Total Asset Turnover | 0.248 |
BIAF Liquidity
| Current Ratio | 1.767 |
| Quick Ratio | 1.759 |
| Cash Ratio | 1.255 |
BIAF Profitability
| Gross Margin | 21.403 |
| Operating Margin | -314.836 |
| Pretax Margin | -312.577 |
| Net Margin | -313.406 |
| Return on Assets | -77.80 |
| Return on Equity | -99.845 |
| Return on Total Capital | -123.362 |
| Return on Invested Capital | -93.282 |
BIAF Capital Structure
| Total Debt to Total Equity | 32.514 |
| Total Debt to Total Capital | 24.536 |
| Total Debt to Total Assets | 19.201 |
| Long-Term Debt to Equity | 23.036 |
| Long-Term Debt to Total Capital | 17.384 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Bioaffinity Technologies Inc. - BIAF
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 4.80K | 2.53M | - |
Sales Growth
| - | - | - | +52,627.44% | - |
Cost of Goods Sold (COGS) incl D&A
| 22.24K | 4.82K | 10.65K | 1.99M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 22.24K | 4.82K | 10.18K | 249.59K | |
Depreciation
| 22.24K | 4.82K | 10.18K | 233.06K | |
Amortization of Intangibles
| - | - | - | 16.53K | - |
COGS Growth
| -44.78% | -78.34% | +121.07% | +18,591.67% | |
Gross Income
| (22.24K) | (4.82K) | (5.85K) | 542.02K | |
Gross Income Growth
| +44.78% | +78.34% | -21.36% | +9,371.69% | |
Gross Profit Margin
| - | - | -121.72% | +21.40% | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.58M | 2.20M | 4.01M | 8.52M | |
Research & Development
| 1.61M | 1.33M | 1.29M | 1.72M | |
Other SG&A
| 972.10K | 875.96K | 2.72M | 6.79M | |
SGA Growth
| -15.39% | -14.72% | +81.89% | +112.60% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 4.28M | 3.12M | 1.65M | |
EBIT after Unusual Expense
| (6.88M) | (5.32M) | (5.67M) | (7.97M) | |
Non Operating Income/Expense
| 1.07K | 424 | 46.71K | 94.33K | |
Non-Operating Interest Income
| 1.07K | 424 | 46.71K | 122.13K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 382.17K | 1.00M | 2.53M | 37.13K | |
Interest Expense Growth
| +77.89% | +162.15% | +152.80% | -98.53% | |
Gross Interest Expense
| 382.17K | 1.00M | 2.53M | 37.13K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (7.27M) | (6.32M) | (8.15M) | (7.92M) | |
Pretax Income Growth
| -119.89% | +12.96% | -28.89% | +2.89% | |
Pretax Margin
| - | - | -169,720.05% | -312.58% | - |
Income Tax
| 2.75K | 1.95K | 2.46K | 20.99K | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (7.27M) | (6.33M) | (8.15M) | (7.94M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (7.27M) | (6.33M) | (8.15M) | (7.94M) | |
Net Income Growth
| -119.77% | +12.96% | -28.89% | +2.66% | |
Net Margin Growth
| - | - | -169,771.25% | -313.41% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (7.27M) | (6.33M) | (8.15M) | (7.94M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (7.27M) | (6.33M) | (8.15M) | (7.94M) | |
EPS (Basic)
| -0.9852 | -0.8575 | -1.8124 | -0.9074 | |
EPS (Basic) Growth
| -119.76% | +12.96% | -111.36% | +49.93% | |
Basic Shares Outstanding
| 7.38M | 7.38M | 4.50M | 8.75M | |
EPS (Diluted)
| -0.9852 | -0.8575 | -1.8124 | -0.9074 | |
EPS (Diluted) Growth
| -119.76% | +12.96% | -111.36% | +49.93% | |
Diluted Shares Outstanding
| 7.38M | 7.38M | 4.50M | 8.75M | |
EBITDA
| (2.58M) | (2.20M) | (4.00M) | (7.72M) | |
EBITDA Growth
| +15.39% | +14.72% | -81.69% | -93.05% | |
EBITDA Margin
| - | - | -83,299.60% | -304.98% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 6.00 | |
| Number of Ratings | 1 | Current Quarters Estimate | -0.14 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -0.68 | |
| Last Quarter’s Earnings | -0.15 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.91 | Next Fiscal Year Estimate | -0.60 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 1 | 1 |
| Mean Estimate | -0.14 | -0.16 | -0.68 | -0.60 |
| High Estimates | -0.14 | -0.16 | -0.68 | -0.60 |
| Low Estimate | -0.14 | -0.16 | -0.68 | -0.60 |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Bioaffinity Technologies Inc. - BIAF
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Bioaffinity Technologies Inc. - BIAF
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 3, 2024 | Steven Girgenti Executive Chairman; Director | 1,065,248 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Peter Sage Knight Director | 117,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Stuart Diamond Director | 99,088 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Maria Zannes President & CEO; Director | 243,322 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Robert Anderson Director | 163,936 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Gary Rubin Director | 146,597 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Jamie Platt Director | 54,748 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Roby P. Joyce Director | 66,615 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 25, 2024 | Steven Girgenti Director | 1,023,168 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.24 per share | 2,291,896.32 |
| Apr 25, 2024 | Steven Girgenti Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 25, 2024 | Maria Zannes President & CEO | 201,242 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.65 per share | 533,291.30 |
| Apr 25, 2024 | Maria Zannes President & CEO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 25, 2024 | Timothy Peter Zannes Secretary, EVP, Gen. Counsel | 75,155 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.16 per share | 87,179.80 |
| Apr 25, 2024 | Timothy Peter Zannes Secretary, EVP, Gen. Counsel | 46,124 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.58 per share | 118,999.92 |
| Apr 25, 2024 | Timothy Peter Zannes Secretary, EVP, Gen. Counsel | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |